Difference between revisions of "Chlorambucil (Leukeran)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Follicular lymphoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 13: | ||
*[[Chronic lymphocytic leukemia]] | *[[Chronic lymphocytic leukemia]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| − | |||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
Revision as of 15:26, 31 May 2022
General information
Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established
Diseases for which it is used
- B-cell lymphoma of mucosa-associated lymphoid tissue
- Chronic lymphocytic leukemia
- Hodgkin lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenström macroglobulinemia
Diseases for which is was used
Patient drug information
- Chlorambucil (Leukeran) package insert[1]
- Chlorambucil (Leukeran) patient drug information (Chemocare)[3]
- Chlorambucil (Leukeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/18/1957: Initial FDA approval
- 11/13/2003: (earliest label available on Drugs@FDA) indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.
Also known as
- Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan
References
Categories:
- Drugs
- Oral medications
- Nitrogen mustards
- Alkylating agents
- Chronic lymphocytic leukemia medications
- Hodgkin lymphoma medications
- Follicular lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Waldenström macroglobulinemia medications
- Breast cancer medications (historic)
- Ovarian cancer medications (historic)
- Testicular cancer medications (historic)
- FDA approved in 1957
- WHO Essential Cancer Medicine